BCDG

Robert Geahlen, Professor of Medicinal Chemistry and Molecular Pharmacology
In breast cancer, tumor progression involves the activation of growth promoting oncogenes and the inactivation of tumor suppressor genes. Understanding the products of these genes and the pathways in which they function is essential for understanding the process of tumorigenesis and for the development of therapeutic strategies. The Syk protein-tyrosine kinase has recently been identified as a tumor suppressor in breast cancer and the goal of our research is to gain an understanding of how Syk functions to suppress the malignant phenotype of breast cancer cells.

For more information on Dr. Geahlen, visit his department website here.